PC15013_ConferencePreview
0 likes156 views
This document provides information about an upcoming conference on oncology endpoints and quality of life assessments taking place in November 2015 in Philadelphia. Attendees will learn about (1) selecting clinical trial endpoints and interpreting quality of life measures to satisfy regulatory requirements, (2) understanding patient needs when designing trials and assessing oncology endpoints, and (3) developing patient-reported outcome tools to evaluate the benefits and risks of treatments. Featured speakers will provide insights and case studies on rapidly changing practices for endpoint selection and validation in oncology trials.
1 of 1
Download to read offline
Recommended
Ksr Clinical Introduction 2009 1
Ksr Clinical Introduction 2009 1brianwilson030999
油
This document provides an overview of clinical research, including what clinical research is, the clinical research process, types of organizations involved, and the steps involved in clinical trials. It then discusses KSR Clinical Research, a consulting firm that places clinical research professionals with pharmaceutical, biotech, and medical device companies as well as research facilities. KSR provides recruitment, project management support, and competencies across various clinical research functions and therapeutic areas.Ksr Clinical Introduction 2009 1
Ksr Clinical Introduction 2009 1DianaFleszar
油
This document provides an overview of clinical research, including what clinical research is, the clinical research process, types of organizations involved, and the steps involved in clinical trials. It then discusses KSR Clinical Research, a consulting firm that places clinical research professionals with pharmaceutical, biotech, and medical device companies as well as research facilities. KSR provides recruitment, project management support, and competencies across various clinical research functions and therapeutic areas.Four Practical Approaches To Managing A More Effective Device Trial
Four Practical Approaches To Managing A More Effective Device TrialDavid Levin
油
This document discusses four practical approaches to managing effective device trials:
1) Consider the appropriate regulatory path and reimbursement strategy to maximize trial and product success.
2) Understand the patient population and customer setting to ensure the trial design reflects real-world use.
3) Incorporate complete trial visibility with technology-driven processes to efficiently manage operations.
4) Clinical trials require significant investment but technology can reduce costs while improving processes like enrollment and data management.What Happens After Your Device is Approved? Collecting Data in the Real World
What Happens After Your Device is Approved? Collecting Data in the Real WorldMedpace
油
In this workshop, Medpace will discuss key considerations for generating real-world evidence and how to apply critical insights in order to drive late-stage clinical research. To listen to this presentation, visit https://vimeo.com/168768256Competitive battlecard 
Competitive battlecard Michael Passanante
油
This document provides a competitive analysis between Thomson Reuters Cortellis for Clinical Trials Intelligence and Trialtrove, a competing clinical trials database owned by Citeline. It outlines the major differentiators of Cortellis, including its coverage of medical device and biomarker trials, analytics/visualizations, modern interface, API integration, and inclusion of additional content like literature and press releases. The document also details how Trialtrove positions itself in the market and recommends tactics for promoting Cortellis as a lower-cost replacement for Trialtrove that provides more value.CTI Landing Page
CTI Landing PageMichael Passanante
油
This document summarizes the Cortellis Clinical Trials Intelligence product. It provides access to over 130,000 clinical trials from around the world across various therapeutic areas. Users can access the data through a web portal or integrate it with other systems using APIs. The platform offers powerful search and filtering capabilities along with dynamic visualizations to analyze trial findings and competitive intelligence. It aims to help users accelerate strategic clinical development decisions and advance personalized medicine.Cortellis for CTI sell sheet
Cortellis for CTI sell sheetMichael Passanante
油
Cortellis for Clinical Trials Intelligence provides a comprehensive resource for clinical trial information to help accelerate strategic decisions. It contains data on over 130,000 global clinical trials, 200,000 press releases, 220,000 literature articles, and 2.25 million articles related to clinical development. The intuitive interface allows users to filter and analyze trial information by various attributes such as indication, intervention, sponsor, phase, and location. Dynamic visualization tools further aid analysis by showing distributions of trial characteristics and timelines in an interactive format.The CRO-Sponsor Interaction: Regulatory Affairs
The CRO-Sponsor Interaction: Regulatory AffairsMedpace
油
The document discusses the evolution of relationships between clinical research organizations (CROs) and sponsors from primarily transactional to preferred partnerships and strategic integration. It outlines keys to productive alliances such as sharing objectives and expertise. The document emphasizes that early engagement between CROs and sponsors is critical for regulatory success and positive relationships. Regulatory affairs experiences a seamless transition across regions and development cycles through CRO support.Clinical Solutions White Paper
Clinical Solutions White PaperMichael Passanante
油
This white paper discusses four ways that pharmaceutical and biotechnology companies can accelerate their clinical portfolio strategy using advanced analytics and clinical trial data and technology. It provides examples of how visualizing clinical trial data over time, benchmarking trial durations, mapping competitive drug pipelines, and comparing safety profiles across trials can provide insights to help with strategic decision making regarding clinical development.Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...
Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...ConferenceForum
油
Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disruptive Innovations ConferenceKey Compliance Issues In Clinical Research: What Sites, CROs, and Start-Ups N...
Key Compliance Issues In Clinical Research: What Sites, CROs, and Start-Ups N...Polsinelli PC
油
Clinical research presents a host of potential compliance and legal risks. This webinar will provide an overview of key legal issues in clinical research applicable to all involved parties, including sponsors, sites and CROs. We will also review recent enforcement activities related to research studies, and provide strategies for addressing issues that arise, both preemptively (through compliance plans) and in response to identified concerns.
Our agenda:
Understand key rules and regulations and how they apply in the context of clinical research
Review key areas of compliance risk, ranging from Medicare reimbursement and billing concerns to informed consent and use of equipment and materials in clinical research
Outline key components of compliance plans and specifics relevant to clinical research
Towse us and eu comparison slides
Towse us and eu comparison slidesOffice of Health Economics
油
This document compares the comparative effectiveness research (CER) and relative effectiveness (RE) evidence environments in the US and Europe. It identifies critical factors and likely scenarios for each region by 2020. Both regions will see increasing demands for CER/RE evidence from payers to demonstrate value. The US will make greater progress in data and analytics capabilities while Europe increases harmonization between regulators and health technology assessors. Adaptive licensing will be implemented in Europe but not the US.Cell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development SolutionsCovance
油
This document summarizes the clinical development solutions offered by Covance for cell and gene therapies. Covance has expertise in oncology, rare diseases, and pediatrics. Their services include clinical studies, biomarkers strategy, companion diagnostics, regulatory and strategic consulting, analytical testing, commercialization support, and post-approval planning. Covance has experience conducting over 40 clinical studies of gene and cell therapies across the US, Europe and Asia involving over 1,100 patients at 263 sites.Fda Cms Pro Industry Initiatives
Fda Cms Pro Industry InitiativesEdward Berger
油
The document discusses several recent "pro-industry" initiatives by the FDA and CMS that are intended to improve responsiveness to industry but have disappointed many companies. It outlines initiatives by each agency, as well as two joint initiatives, including improved information sharing between the agencies. However, the document notes that industry remains doubtful about the initiatives due to ongoing costs, uncertainty, and limitations of some programs. Barriers to successful implementation of the initiatives include limited agency budgets, staffing challenges, and lack of stable leadership.Cell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development SolutionsCovance
油
Cell & Gene Therapy clinical development solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
Observational Studies: Strategic, Operational and Budgetary Considerations
Observational Studies: Strategic, Operational and Budgetary ConsiderationsTTC, llc
油
Observational studies provide important real-world data on drug safety, effectiveness, and value that complement randomized controlled trials. However, conducting observational studies presents unique operational challenges and requires specialized skills different from traditional clinical trials. If properly designed and managed, observational studies can fulfill post-approval regulatory obligations in a cost-effective manner by generating real-world evidence on safety, clinical outcomes, economics, and patient experiences.Carevive featured in Advisory Board Company Oncology Rountable
Carevive featured in Advisory Board Company Oncology RountableCarevive
油
Make Advance Care Planning a Critical Component resulted in increased physician adherence to QOPI metrics.Accelerating Patient Care with Real World Evidence
Accelerating Patient Care with Real World EvidenceCitiusTech
油
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.CLQ Overview Deck
CLQ Overview DeckDavid Dornstreich
油
CancerLinQ aims to harness big data to improve cancer care by learning from every patient. It faces challenges of integrating diverse data types from genomics to behaviors. Its goals are precision, personalized medicine through molecular profiling of individual cancers. As clinical trials enroll few patients, CancerLinQ would provide real-world data from electronic health records to uncover new insights. When deployed, it will analyze de-identified patient records to uncover care patterns, allow comparing care to guidelines and peers, and provide evidence-based guidance. This has the potential to improve outcomes for patients and quality for providers and researchers.SITIST 2015 Dev - Turning big data into presicion medicine real life examples
SITIST 2015 Dev - Turning big data into presicion medicine real life examplessitist
油
Big data in healthcare comes from a variety of sources and formats including clinical trials, patient records, medical literature, genomic data, and medical imaging. This large volume of data presents challenges to make it accessible and usable. SAP offers platforms and solutions to unlock the value in healthcare big data by enabling precision medicine through analyzing diverse clinical and genomic data sources. Examples include SAP's partnership with ASCO on the CancerLinQ project to link oncology data and improve cancer treatment, and SAP Medical Research Insights deployed at the National Center for Tumor Diseases in Heidelberg, Germany.12 case studies on doctor reputation management teaser
12 case studies on doctor reputation management teaserHealthcare Marketing Center
油
This document discusses 12 case studies about physician reputations and return on investment from internet marketing. It summarizes the methodology used, which involves market research on patient and referring physician online behaviors to create targeted website content and ads. A key finding is that patient and physician traffic to websites was diverting to sites like Google and physician rating sites for background checks. Improving reputation management and promoting doctors was found to increase new patient volumes and decrease campaign costs. Two case studies describe specific examples of how poor reviews negatively impacted business and how one hospital's profiles could be better represented. The document promotes contacting the company to receive the full 12 case studies analysis and learn how to improve return on investment from addressing online reputation issues.2016 LabHIT Vision
2016 LabHIT VisionMegan Sawchuk
油
The document discusses the CDC's LabHIT program which aims to facilitate laboratory test ordering and reporting in electronic health records. The program develops and disseminates standardized terminology and code sets to support clinical data capture and interoperability. It also works with various stakeholders to engage in terminology development, promote semantic interoperability, and ensure usability and patient safety. The long-term goal is a single national reference database for recommended vocabulary sets to achieve full-scale interoperability for laboratory data.Adaptive Designs for Medical Device Clinical Studies - By Compliance Global ...
Adaptive Designs for Medical Device Clinical Studies - By Compliance Global ...Compliance Global Inc
油
US and EU regulatory requirements for adaptive clinical trials, its rationale, logistics and differences for drug, biologic and medical devicesDevelopments in Clinical Trials
Developments in Clinical TrialsMichael Passanante
油
This document provides an overview of developments in clinical trial design, with a focus on adaptive designs. It discusses how adaptive designs allow trials to be modified based on accumulating data to make trials more efficient. The number of adaptive design trials has been growing annually by an average of 11.5%. Various types of adaptive designs are described, including exploratory, confirmatory, seamless, and enrichment designs. Specific examples highlight how adaptive designs can help drop ineffective treatments earlier and identify more promising treatments. Regulatory progress on adaptive designs and remaining hurdles are also discussed.Xcellerate速 Monitoring 
Xcellerate速 Monitoring Covance
油
Leverage near real-time data with risk-based, adaptive site monitoring to identify issues and trigger targeted actions that proactively mitigate threats to a clinical trial's success.Evidence-Generation in Digital Healthcare: Demonstrating Value. Prakash Navar...
Evidence-Generation in Digital Healthcare: Demonstrating Value. Prakash Navar...Upgraded - Health Startup Association of Finland
油
Presented in Upgraded Life Festival 31.5.2016 by Prakash Navaratnam, Sygeny Oy. http://www.upgradedlifefestival.com/ Infographic- Improve Clinical Trial Participation with Mobile Apps
Infographic- Improve Clinical Trial Participation with Mobile AppsDiaspark
油
Mobile apps are pivotal to patient recruitment & retention in clinical trials, we have done research on changing trends &d challenges in clinical trial patient recruitment & retention.Marketing Summary - sales presentatioin
Marketing Summary - sales presentatioinMichael Passanante
油
This document summarizes Michael Passanante's clinical solutions marketing plan for 2013. The plan's key goals are to enhance awareness of their clinical solutions suite, ensure customer-facing staff are trained, and develop new clinical leads. The plan outlines strategies to displace competitors, upsell existing products, and expand into new areas like academic customers. Metrics include securing pilot programs, generating revenue, and developing sales qualified leads across various campaigns promoting clinical trial, analytics, and services offerings throughout 2013.ExL Pharma Clinical Trials Phase I and Phase IIa Conference Brochure: Phase 1...
ExL Pharma Clinical Trials Phase I and Phase IIa Conference Brochure: Phase 1...bryonmain
油
There is a pill or treatment for almost everything, or at least, that is how it seems. However, the amount of effort that goes into a pill or treatment before it is launched is extensive, expensive and often inefficient.
Efficiency and innovation go hand-in-hand with R&D and the development of clinical trials, however, FDA regulations and clinical trial standardization end up stifling these two key factors. This leads to drawn out processes that cost companies hundreds of millions of dollars before the drugs hit the market. Efforts have been made to increase efficiency in phase I/IIA with some companies changing their clinical trial manifestos to suit the available patient population at clinical sites, but more emphasis should be placed on creating more efficient processes for first in human studies by optimizing pharmacokinetics/pharmacodynamics, dosage selection, technological advancements to improve efficacy and structured patient mapping to increase successful trial and patient recruitment opportunities.
This program will give delegates the opportunity to share proven strategies between companies to help increase efficiency in this space and streamline processes to cut down costs. This event will bring together large and small companies and experts in this space to share best practices to decrease the financial drain theses phases have on the overall clinical trial budget. Life science corporations need the most up-to-date tools and practices to increase success by streamlining processes, sharing successful biomarker strategies, anticipating dosing quantities, and optimizing healthy or specialty patient recruitment and retention. Current strategies include patient mapping before organizing and setting up a clinical space, tailoring early phase clinical trials to patient populations, purchasing biological samples from collection companies, and trying to accelerate the process by submitting for breakthrough therapy designation.
Top Reasons To Attend
Identify Compound Development Strategies to Optimize Success in Clinical Trials
Learn Best Practices for Early Decision-Making Through Analysis of Biomarker Utility in Drug Development
Utilize Analytical Technology to Evaluate Multiple Configurations of a Small Molecule to Increase the Feasibility of Drug in Clinical Trials
Implement Adaptive Design in Proof of Concept Studies to Increase Efficiency, Decrease Time and Decrease Overall Cost
Explore the Seamless Development of Phase I to Phase II in Clinical Trials
NINE Case Studies and a Panel Session on Early Phase Clinical Trial Strategies116797_BALS182-1
116797_BALS182-1isaac nandikove
油
This document provides information about a clinical quality and compliance masterclass conference taking place on June 16th and 17th, 2016 in Vienna. The conference will focus on managing clinical quality for greater compliance, effectiveness, and audit readiness. Over the two days, there will be keynote speakers from major pharmaceutical companies, case studies, and workshops on topics such as on-site quality improvements, inspection readiness, quality risk management, and third-party oversight. Attendees will include quality assurance professionals from pharmaceutical and biotech companies as well as CROs.More Related Content
What's hot (20)
Clinical Solutions White Paper
Clinical Solutions White PaperMichael Passanante
油
This white paper discusses four ways that pharmaceutical and biotechnology companies can accelerate their clinical portfolio strategy using advanced analytics and clinical trial data and technology. It provides examples of how visualizing clinical trial data over time, benchmarking trial durations, mapping competitive drug pipelines, and comparing safety profiles across trials can provide insights to help with strategic decision making regarding clinical development.Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...
Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...ConferenceForum
油
Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disruptive Innovations ConferenceKey Compliance Issues In Clinical Research: What Sites, CROs, and Start-Ups N...
Key Compliance Issues In Clinical Research: What Sites, CROs, and Start-Ups N...Polsinelli PC
油
Clinical research presents a host of potential compliance and legal risks. This webinar will provide an overview of key legal issues in clinical research applicable to all involved parties, including sponsors, sites and CROs. We will also review recent enforcement activities related to research studies, and provide strategies for addressing issues that arise, both preemptively (through compliance plans) and in response to identified concerns.
Our agenda:
Understand key rules and regulations and how they apply in the context of clinical research
Review key areas of compliance risk, ranging from Medicare reimbursement and billing concerns to informed consent and use of equipment and materials in clinical research
Outline key components of compliance plans and specifics relevant to clinical research
Towse us and eu comparison slides
Towse us and eu comparison slidesOffice of Health Economics
油
This document compares the comparative effectiveness research (CER) and relative effectiveness (RE) evidence environments in the US and Europe. It identifies critical factors and likely scenarios for each region by 2020. Both regions will see increasing demands for CER/RE evidence from payers to demonstrate value. The US will make greater progress in data and analytics capabilities while Europe increases harmonization between regulators and health technology assessors. Adaptive licensing will be implemented in Europe but not the US.Cell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development SolutionsCovance
油
This document summarizes the clinical development solutions offered by Covance for cell and gene therapies. Covance has expertise in oncology, rare diseases, and pediatrics. Their services include clinical studies, biomarkers strategy, companion diagnostics, regulatory and strategic consulting, analytical testing, commercialization support, and post-approval planning. Covance has experience conducting over 40 clinical studies of gene and cell therapies across the US, Europe and Asia involving over 1,100 patients at 263 sites.Fda Cms Pro Industry Initiatives
Fda Cms Pro Industry InitiativesEdward Berger
油
The document discusses several recent "pro-industry" initiatives by the FDA and CMS that are intended to improve responsiveness to industry but have disappointed many companies. It outlines initiatives by each agency, as well as two joint initiatives, including improved information sharing between the agencies. However, the document notes that industry remains doubtful about the initiatives due to ongoing costs, uncertainty, and limitations of some programs. Barriers to successful implementation of the initiatives include limited agency budgets, staffing challenges, and lack of stable leadership.Cell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development SolutionsCovance
油
Cell & Gene Therapy clinical development solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
Observational Studies: Strategic, Operational and Budgetary Considerations
Observational Studies: Strategic, Operational and Budgetary ConsiderationsTTC, llc
油
Observational studies provide important real-world data on drug safety, effectiveness, and value that complement randomized controlled trials. However, conducting observational studies presents unique operational challenges and requires specialized skills different from traditional clinical trials. If properly designed and managed, observational studies can fulfill post-approval regulatory obligations in a cost-effective manner by generating real-world evidence on safety, clinical outcomes, economics, and patient experiences.Carevive featured in Advisory Board Company Oncology Rountable
Carevive featured in Advisory Board Company Oncology RountableCarevive
油
Make Advance Care Planning a Critical Component resulted in increased physician adherence to QOPI metrics.Accelerating Patient Care with Real World Evidence
Accelerating Patient Care with Real World EvidenceCitiusTech
油
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.CLQ Overview Deck
CLQ Overview DeckDavid Dornstreich
油
CancerLinQ aims to harness big data to improve cancer care by learning from every patient. It faces challenges of integrating diverse data types from genomics to behaviors. Its goals are precision, personalized medicine through molecular profiling of individual cancers. As clinical trials enroll few patients, CancerLinQ would provide real-world data from electronic health records to uncover new insights. When deployed, it will analyze de-identified patient records to uncover care patterns, allow comparing care to guidelines and peers, and provide evidence-based guidance. This has the potential to improve outcomes for patients and quality for providers and researchers.SITIST 2015 Dev - Turning big data into presicion medicine real life examples
SITIST 2015 Dev - Turning big data into presicion medicine real life examplessitist
油
Big data in healthcare comes from a variety of sources and formats including clinical trials, patient records, medical literature, genomic data, and medical imaging. This large volume of data presents challenges to make it accessible and usable. SAP offers platforms and solutions to unlock the value in healthcare big data by enabling precision medicine through analyzing diverse clinical and genomic data sources. Examples include SAP's partnership with ASCO on the CancerLinQ project to link oncology data and improve cancer treatment, and SAP Medical Research Insights deployed at the National Center for Tumor Diseases in Heidelberg, Germany.12 case studies on doctor reputation management teaser
12 case studies on doctor reputation management teaserHealthcare Marketing Center
油
This document discusses 12 case studies about physician reputations and return on investment from internet marketing. It summarizes the methodology used, which involves market research on patient and referring physician online behaviors to create targeted website content and ads. A key finding is that patient and physician traffic to websites was diverting to sites like Google and physician rating sites for background checks. Improving reputation management and promoting doctors was found to increase new patient volumes and decrease campaign costs. Two case studies describe specific examples of how poor reviews negatively impacted business and how one hospital's profiles could be better represented. The document promotes contacting the company to receive the full 12 case studies analysis and learn how to improve return on investment from addressing online reputation issues.2016 LabHIT Vision
2016 LabHIT VisionMegan Sawchuk
油
The document discusses the CDC's LabHIT program which aims to facilitate laboratory test ordering and reporting in electronic health records. The program develops and disseminates standardized terminology and code sets to support clinical data capture and interoperability. It also works with various stakeholders to engage in terminology development, promote semantic interoperability, and ensure usability and patient safety. The long-term goal is a single national reference database for recommended vocabulary sets to achieve full-scale interoperability for laboratory data.Adaptive Designs for Medical Device Clinical Studies - By Compliance Global ...
Adaptive Designs for Medical Device Clinical Studies - By Compliance Global ...Compliance Global Inc
油
US and EU regulatory requirements for adaptive clinical trials, its rationale, logistics and differences for drug, biologic and medical devicesDevelopments in Clinical Trials
Developments in Clinical TrialsMichael Passanante
油
This document provides an overview of developments in clinical trial design, with a focus on adaptive designs. It discusses how adaptive designs allow trials to be modified based on accumulating data to make trials more efficient. The number of adaptive design trials has been growing annually by an average of 11.5%. Various types of adaptive designs are described, including exploratory, confirmatory, seamless, and enrichment designs. Specific examples highlight how adaptive designs can help drop ineffective treatments earlier and identify more promising treatments. Regulatory progress on adaptive designs and remaining hurdles are also discussed.Xcellerate速 Monitoring
Xcellerate速 Monitoring Covance
油
Leverage near real-time data with risk-based, adaptive site monitoring to identify issues and trigger targeted actions that proactively mitigate threats to a clinical trial's success.Evidence-Generation in Digital Healthcare: Demonstrating Value. Prakash Navar...
Evidence-Generation in Digital Healthcare: Demonstrating Value. Prakash Navar...Upgraded - Health Startup Association of Finland
油
Presented in Upgraded Life Festival 31.5.2016 by Prakash Navaratnam, Sygeny Oy. http://www.upgradedlifefestival.com/ Infographic- Improve Clinical Trial Participation with Mobile Apps
Infographic- Improve Clinical Trial Participation with Mobile AppsDiaspark
油
Mobile apps are pivotal to patient recruitment & retention in clinical trials, we have done research on changing trends &d challenges in clinical trial patient recruitment & retention.Marketing Summary - sales presentatioin
Marketing Summary - sales presentatioinMichael Passanante
油
This document summarizes Michael Passanante's clinical solutions marketing plan for 2013. The plan's key goals are to enhance awareness of their clinical solutions suite, ensure customer-facing staff are trained, and develop new clinical leads. The plan outlines strategies to displace competitors, upsell existing products, and expand into new areas like academic customers. Metrics include securing pilot programs, generating revenue, and developing sales qualified leads across various campaigns promoting clinical trial, analytics, and services offerings throughout 2013.Adaptive Designs for Medical Device Clinical Studies - By Compliance Global ...
Adaptive Designs for Medical Device Clinical Studies - By Compliance Global ...Compliance Global Inc
油
Evidence-Generation in Digital Healthcare: Demonstrating Value. Prakash Navar...
Evidence-Generation in Digital Healthcare: Demonstrating Value. Prakash Navar...Upgraded - Health Startup Association of Finland
油
Similar to PC15013_ConferencePreview (20)
ExL Pharma Clinical Trials Phase I and Phase IIa Conference Brochure: Phase 1...
ExL Pharma Clinical Trials Phase I and Phase IIa Conference Brochure: Phase 1...bryonmain
油
There is a pill or treatment for almost everything, or at least, that is how it seems. However, the amount of effort that goes into a pill or treatment before it is launched is extensive, expensive and often inefficient.
Efficiency and innovation go hand-in-hand with R&D and the development of clinical trials, however, FDA regulations and clinical trial standardization end up stifling these two key factors. This leads to drawn out processes that cost companies hundreds of millions of dollars before the drugs hit the market. Efforts have been made to increase efficiency in phase I/IIA with some companies changing their clinical trial manifestos to suit the available patient population at clinical sites, but more emphasis should be placed on creating more efficient processes for first in human studies by optimizing pharmacokinetics/pharmacodynamics, dosage selection, technological advancements to improve efficacy and structured patient mapping to increase successful trial and patient recruitment opportunities.
This program will give delegates the opportunity to share proven strategies between companies to help increase efficiency in this space and streamline processes to cut down costs. This event will bring together large and small companies and experts in this space to share best practices to decrease the financial drain theses phases have on the overall clinical trial budget. Life science corporations need the most up-to-date tools and practices to increase success by streamlining processes, sharing successful biomarker strategies, anticipating dosing quantities, and optimizing healthy or specialty patient recruitment and retention. Current strategies include patient mapping before organizing and setting up a clinical space, tailoring early phase clinical trials to patient populations, purchasing biological samples from collection companies, and trying to accelerate the process by submitting for breakthrough therapy designation.
Top Reasons To Attend
Identify Compound Development Strategies to Optimize Success in Clinical Trials
Learn Best Practices for Early Decision-Making Through Analysis of Biomarker Utility in Drug Development
Utilize Analytical Technology to Evaluate Multiple Configurations of a Small Molecule to Increase the Feasibility of Drug in Clinical Trials
Implement Adaptive Design in Proof of Concept Studies to Increase Efficiency, Decrease Time and Decrease Overall Cost
Explore the Seamless Development of Phase I to Phase II in Clinical Trials
NINE Case Studies and a Panel Session on Early Phase Clinical Trial Strategies116797_BALS182-1
116797_BALS182-1isaac nandikove
油
This document provides information about a clinical quality and compliance masterclass conference taking place on June 16th and 17th, 2016 in Vienna. The conference will focus on managing clinical quality for greater compliance, effectiveness, and audit readiness. Over the two days, there will be keynote speakers from major pharmaceutical companies, case studies, and workshops on topics such as on-site quality improvements, inspection readiness, quality risk management, and third-party oversight. Attendees will include quality assurance professionals from pharmaceutical and biotech companies as well as CROs.pc15007_brochure
pc15007_brochureDaria Binder
油
This document provides information about an upcoming conference on cardiovascular safety and efficacy in drug development. The conference will take place February 10-11, 2015 in Alexandria, VA and feature speakers from major pharmaceutical companies and academic institutions. Topics will include evolving strategies for cardiac monitoring, replacing thorough QT studies, identifying drug interactions, and utilizing new technologies like circulating biomarkers and advanced imaging. The goal is to discuss optimizing cardiac safety assessment from pre-clinical through approval to improve drug development.pc15222_brochure
pc15222_brochureAmy Ripston
油
This document announces a conference on risk-based monitoring in clinical trials taking place on November 5-6, 2015 in Philadelphia. The conference will discuss how risk-based monitoring involves more than just monitoring and focuses on managing risk throughout the entire clinical trial process from protocol design through analysis. Speakers will address topics like how FDA inspections have adapted to risk-based monitoring, the impact of risk-based monitoring on the role of monitors, integrating technology like eSource data capture to enable risk-based trials, and how smaller organizations can implement risk-based monitoring.Four strategies to upgrade clinical trial quality in this computerized world ...
Four strategies to upgrade clinical trial quality in this computerized world ...Pubrica
油
Biostatistics Services is important for collecting, reviewing, presenting, and interpreting data in clinical research.
Applications of clinical biostatistics services are in different areas, such as epidemiology, clinical trials, population genetics, the biology of structures, and more.
Reference : https://pubrica.com/services/research-services/biostatistics-and-statistical-programming-services/
Continue Reading: http://bit.ly/36nwtcs
Why Pubrica?
When you order our services, Plagiarism free|onTime|outstanding customer support|Unlimited Revisions support|High-quality Subject Matter Experts.
Contact us :
Web:https://pubrica.com/
Blog:https://pubrica.com/academy/
Email:sales@pubrica.com
WhatsApp : +91 9884350006
United Kingdom: +44- 74248 10299
Blueprints to blue sky analyzing the challenges and solutions for IHC compa...
Blueprints to blue sky analyzing the challenges and solutions for IHC compa...Candy Smellie
油
Manual assessment of biomarker expression is associated with significant inter- and intra reader variability. In some cases there are also limitations when it comes to sensitivity and specificity of manual biomarker assessment.
In one example to the left, the pure contribution of inter-reader variability associated with Ki67 assessment was quantified across 20 tumors and 126 participating labs. In that study, it was demonstrated how image analysis can be used to significantly reduce inter-reader variability.
In a another study, the National Danish Validation study of Her2, it was demonstrated how improved sensitivity/specificity of quantitative HER2 protein expression wrt gene amplification lead to significant cost savings in reflex testing.
By automating aspects of stain quality control, it will become scalable to he point where EQA organizations may be able and willing to offer more frequent perhaps even on-demand proficiency testing and calibration services.
It is possible that objective and quantitative standards will contribute to improve compliance with protocol recommendations.
In clinical multi-center trials it will be easier to standardize and monitor data from each center.
And it is our hope tha larger diagnostic pathology labs will be able to benefit from such a method by closely monitoring drift in staining quality for biomarkers. Customized Oncology Development Solutions: Clinical Trials Designed Around You速
Customized Oncology Development Solutions: Clinical Trials Designed Around You速Covance
油
Covance provides customized clinical trial solutions and services for oncology drug development. Their services include utilizing patient lab data to assess trial feasibility and identify eligible patients, scientific consultation in precision medicine areas, and selecting investigator sites with the right patients and experience. Covance aims to help clients accelerate development timelines, improve the probability of success, and deliver trials on budget.SMi Group's Adaptive Designs in Clinical Trials conference
SMi Group's Adaptive Designs in Clinical Trials conferenceDale Butler
油
This document summarizes an upcoming conference on adaptive designs in clinical trials taking place from April 20-21, 2015 in London. The conference will focus on topics such as Bayesian adaptive designs, subgroup selection in clinical trials, integrating real-world patient data into adaptive trials, and designing biomarker-driven multi-arm multi-stage cancer trials. Speakers will discuss challenges with adaptive designs and their use in different therapeutic areas like neurodegenerative diseases. Participants can also register for optional half-day workshops on April 22nd focusing on Bayesian clinical trial designs and navigating international regulatory landscapes for adaptive trials.Cortellis for Clinical Trials Message Platform
Cortellis for Clinical Trials Message PlatformMichael Passanante
油
Cortellis for Clinical Trials Intelligence provides powerful resources to accelerate clinical trial development decisions and portfolio strategy. It allows users to leverage clinical trial information integrated with other scientific and competitive intelligence to accelerate a wide variety of strategic clinical development decisions. The platform provides over 130,000 global clinical trials from over 20,000 sources, with dynamic visual analytic tools that reduce time spent analyzing information to support fact-based decision making.Delivering real world evidence to demonstrate product safety and value
Delivering real world evidence to demonstrate product safety and valueKishan Patel, MBA
油
This document discusses how observational research and patient registries can provide real-world evidence on product safety and effectiveness. It outlines Quintiles' capabilities in this area, including experience conducting 195 patient registries and observational studies involving over 9 million patients. Quintiles claims it can help companies demonstrate products' performance in various populations and support regulatory and coverage decisions through generating real-world evidence.Nutraceutical Clinical Trial importance and checklist for outsourcing.
Nutraceutical Clinical Trial importance and checklist for outsourcing.foodresearch
油
Checklist for choosing the right CRO for outsourcing your nutraceutical clinical trial and benefits of outsourcing in clinical trials
Cancer Genetics Investor Deck
Cancer Genetics Investor DeckRedChip Companies, Inc.
油
This document provides an overview of Cancer Genetics, Inc. (CGI) and their focus on being an oncology diagnostics partner from bench to bedside. Some key points:
- CGI utilizes targeted acquisitions and collaborations with research institutions to expand their testing capabilities and global footprint.
- They have a proprietary portfolio of over 20 genomic tests and panels focused on cancers like blood cancers, lymphomas, lung cancer, and solid tumors.
- CGI partners with leading biopharma companies, supporting over 120 clinical trials with testing and services. They have contracts with 8 of the top 10 biopharma companies.Nutraceutical Clinical Trial importance and checklist for outsourcing.
Nutraceutical Clinical Trial importance and checklist for outsourcing.foodresearch
油
Checklist for choosing the right CRO for outsourcing your nutraceutical clinical trial and benefits of outsourcing in clinical trials
Nutraceutical Clinical Trial importance and checklist for outsourcing.
Nutraceutical Clinical Trial importance and checklist for outsourcing.foodresearch
油
Checklist for choosing the right CRO for outsourcing your nutraceutical clinical trial and benefits of outsourcing in clinical trials
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...MedStatix, LLC
油
Improving Patient Experience. Improving Practice Performance.
MedStatix, LLC, offers a WHITE LABELED, cloud-based specialty-specific patient experience survey platform that is bundled and/or resold by leading EMR/EHRs and other integrated healthcare service providers as a value-add to their products.
The patient experience platform uses data science and predictive analytics learned from data hosted on the platform to enable healthcare providers to improve quality of care, patient retention rates and risk profiles of physician practices.
The patient experience platform pinpoints specific, actionable problems where practices can improve their service through its easy-to-implement, yet sophisticated technology solution for monitoring and measuring patient experience by each provider across an organization.
With over a decade delivering over one million patient surveys for over 25 pharmaceutical brands, as well as customer feedback platforms and analytics for Fortune-class brands, MedStatix enables their resellers to provide their customers with exceptional practice improvement opportunities.Integrate RWE into clinical development
Integrate RWE into clinical developmentIMSHealthRWES
油
With greater application of RWE throughout the pharmaceutical
lifecycle, learnings are emerging that offer guidance for
approaches to derive the maximum value. This article captures
the authors experience at a leading international biotech, with
insights for smoothing RWE assimilation into clinical
development and realizing the benefits it brings.BBCR Innovation Approach
BBCR Innovation ApproachBoston Biotech Clinical Research
油
The challenges of our time require a strategic approach to build the drugs and devices of the future. Our broad knowledge and long-term experience allow us to provide our customers with Innovative solutions and risk management.Highlights from ExL Pharma's 4th Latin America Clinical Trials
Highlights from ExL Pharma's 4th Latin America Clinical TrialsExL Pharma
油
This document summarizes presentations from ExLPharma's 4th Latin America Clinical Trials conference. It discusses topics like IRB collaboration between institutions, using microfinance organizations' infrastructure to aid in clinical trial recruitment and retention, ensuring quality in clinical research, and considerations for outsourcing clinical research functions. Key aspects covered include developing countries' IRB competencies, challenges and benefits of the clinical trial-microfinance partnership model, importance of quality oversight and planning, and factors to consider for outsourcing research and development activities.4.Out sourcing BA&BE to CRO
4.Out sourcing BA&BE to CROKrishnapriyaVH1
油
- CROs (Contract Research Organizations) are organizations contracted by pharmaceutical companies to conduct clinical trials and other drug development services. Outsourcing to CROs allows companies to reduce costs and accelerate drug development timelines without requiring large in-house capabilities.
- Key responsibilities of CROs include managing clinical sites and trials, conducting bioanalytical testing, and performing pharmacokinetic analyses. Proper qualification of CROs and ongoing communication are important for successful partnerships. Outsourcing can increase capacity and reduce development cycles for pharmaceutical sponsors.Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...SC CTSI at USC and CHLA
油
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Virtual, & Decentralized Clinical TrialsDigital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...SC CTSI at USC and CHLA
油
More from Daria Binder (7)
pc15136_brochure
pc15136_brochureDaria Binder
油
This document provides information about an annual conference on commercial contract strategies for the biopharma industry. The conference will take place June 22-23, 2015 in Philadelphia and focus on topics like preventing revenue leakage, simplifying rebate administration, and navigating complexities of group purchasing organization membership and class of trade. It lists speakers from companies like Amerinet, Dr. Reddy's Laboratories, Johnson & Johnson, and Pfizer. Attendees can choose from workshops on optimizing data sets for EDI improvements or dissecting the 340B drug pricing program. The event is aimed at executives involved in contracts, chargebacks, rebates, and other areas.PC15164_ConferencePreview
PC15164_ConferencePreviewDaria Binder
油
The document summarizes an upcoming medical communications summit that will focus on:
1) Four breakout boot camps allowing customization of the conference experience on topics like device-specific medical affairs and M&A strategies.
2) Innovative initiatives in medical communications departments to shape the field.
3) Ground-breaking case studies to provide teams with strategies for delivering more impactful information in a customer-focused era.pc15098_brochure
pc15098_brochureDaria Binder
油
This document provides information about an upcoming conference on abuse deterrent formulations. The two-day conference will be held on May 19-20, 2015 at the DoubleTree by Hilton in Silver Spring, MD. It will focus on strategies for developing opioid and non-opioid drugs with reduced abuse potential, including best practices for clinical trials, gaining FDA approval, and communicating claims. Speakers will include representatives from pharmaceutical companies and regulatory experts. Attendees will learn about formulation technologies, clinical study design, regulatory pathways, and policy issues regarding abuse deterrent drugs.PC15270_ConferencePreview
PC15270_ConferencePreviewDaria Binder
油
The document announces an upcoming conference on September 24-25, 2015 in Boston on collaboration and transaction accounting for small to mid-sized life sciences companies. The conference will provide industry thought leaders an opportunity to benchmark practices and identify best practices for accounting standards related to complex collaborative arrangements. Confirmed speakers include executives from Flex Pharma, Ironwood Pharmaceuticals, Merrimack Pharmaceuticals, and Ocata Therapeutics who will discuss topics like the evolution of revenue standards, optimizing IP arrangements, and tax considerations for collaborative agreements. The conference is aimed at CFOs, controllers and other finance executives involved in accounting, reporting, transactions, and contracts within the pharmaceutical, biotech or medical device industries.PC15218_preview
PC15218_previewDaria Binder
油
This document announces a conference on hub models and program design for pharmaceutical companies. The conference will be held in San Diego on September 29-30, 2015 and will provide information to help pharmaceutical manufacturers implement hub strategies and maximize patient services. Executives in areas like patient access, product management, reimbursement, and specialty services will benefit from attending. The conference will also benefit hub service providers, specialty pharmacies, distributors, and technology companies. Attendees can network with colleagues and learn how to improve hub management, tailor services, collect data, and collaborate with physicians. Several pharmaceutical companies have already confirmed their participation.pc15257_brochure original
pc15257_brochure originalDaria Binder
油
The document provides information about an upcoming conference on clinical data disclosure and transparency taking place on January 28-29, 2015 in Philadelphia, PA. It lists the conference sponsors and over 30 speakers from 20+ companies that will discuss approaches to data sharing and ensuring compliance with regulations. Attendees will include chief medical officers, general counsels, and clinical professionals involved in disclosure, clinical operations, and regulatory affairs. The conference will explore implications of increased transparency requirements and navigating public disclosure on platforms like ClinicalTrials.gov and EudraCT.pc15147_brochure
pc15147_brochureDaria Binder
油
The 3rd Annual Investigator Initiated and Sponsored Research conference will take place January 21-22, 2015 in Philadelphia, PA. The conference will provide insights from industry leaders on building standards for determining fair market value, transparency, and reporting practices for investigator initiated studies, investigator sponsored trials, and cooperative group research. Participants can choose from in-depth workshops, breakout sessions, and think tanks on optimizing global research, conducting fair market value analysis, leveraging master protocols, and developing tactics for negotiating investigator initiated study agreements. The goal is to create a platform for developing standards in these important areas of clinical research.PC15013_ConferencePreview
- 1. Plus! Choose from two comprehensive pre-conference workshops: A: Oncology Imaging Endpoint Assessment | B: Surrogate Endpoints and Accelerated Drug Approval Pathways C O N F E R E N C E P R E V I E W * Life Sciences *This is preliminary conference information. Topics, agenda and speaker names are subject to change without notice. November 2-3, 2015 Philadelphia, PA Validate Endpoints, Interpret QOL Scores and Incorporate Patient Preferences to Satisfy Regulatory Requirements for Reliability and Validity Oncology Endpoints & QOL Assessments Who Should Attend You will benefit from attending this event if you are a manager, associate director, director or vice president from a biotech, pharmaceutical, medical device company or academic research institute with responsibilities or involvement in the following areas: Oncology Heads Program Leads Medical Affairs HEOR PRO Clinical Research/Outcomes Data Management/Statistics This conference will also benefit consultants, CROs, imaging and technology vendors working with the above audience. Although the FDA has long-time considered OS as the gold standard for oncology endpoints, there has been a push for the inclusion of patient preferences and benefit-risk assessments, leading to the acceptance of surrogate endpoints based on QOL measures. CBIs Oncology Endpoints and QOL Assessments provides insight into the rapidly changing field of oncology clinical trials including case studies and perspectives surrounding endpoint selection, QOL interpretation and the development of PRO measures to ensure validity and integrity of the trial to support regulatory approval. Benchmark against leading oncology thought-leaders: A Great Place to Meet Your Market! Take advantage of the best opportunity to meet potential clients face-to-face. Build relationships while demonstrating thought leadership and sharing expertise. For more information on how to position your company as a sponsor or exhibitor, contact: Taylor Biggers 339-298-2108 | taylor.biggers@cbinet.com Understand patient needs when designing clinical trials and assessing oncology endpoints in terms of disease, treatment and impact of therapy Develop patient reported outcome tools to identify benefit-risk assessments of treatments Create strategies to validate endpoints without subjecting the immune system to toxicities in immuno-oncology clinical trials Obtain PRO label claims in oncology trials by creating system indexes Ira Klein, Medical Director, Aetna Scott Megaffin, President, Churchill Pharmaceuticals, LLC David Cella, Ph.D., Director, Patient-Centered Outcomes, Institute of Public Health for Medicine Pablo Lapuerta, M.D., Executive Vice President and Chief Medical Officer, Lexicon Pharmaceuticals Featured Speakers: